Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed)

The National Institute of Mental Health (NIMH), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services, has issued a federal single-source Notice of Funding Opportunity titled “Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed).” The funding opportunity supports continuation of the AMP SCZ Data Processing, Analysis, and Coordination Center to complete the processing, harmonization, coordination, and analysis of longitudinal multimodal biomarker and clinical outcome data collected over a 24-month period from individuals at clinical high risk for schizophrenia. The initiative aligns with NIMH’s mission to transform the understanding and treatment of mental illnesses through research that advances prevention, recovery, and cure. The opportunity is issued as a cooperative agreement under activity code U24 and specifically supports a large-scale national research infrastructure and coordination effort associated with the AMP SCZ initiative. The AMP SCZ initiative is described as one of the most comprehensive longitudinal studies ever conducted in individuals at clinical high risk for schizophrenia. The study has already recruited more than 2,600 participants and includes extensive longitudinal assessments involving clinical evaluations, neuroimaging, neurophysiology, genetics, cognitive measures, speech and facial expression analysis, fluid biomarkers, and digital assessments. According to the NOFO, the complete data set is not expected to be finalized until June 2027. The continuation funding is intended to maintain continuity of the existing data processing pipeline, continue data curation through the full 24-month observation period, complete primary analyses, and support dissemination and coordination activities. The funded DPACC is expected to aggregate raw data across collection sites, implement quality control procedures, maintain centralized data infrastructure, monitor retention and protocol adherence, coordinate the multisite research network, and identify predictive biomarkers and schizophrenia risk stratifications using multimodal data. The award mechanism is a cooperative agreement, meaning NIH staff will have substantial scientific and programmatic involvement during project execution. The NOFO states that NIMH intends to commit approximately $5,000,000 in fiscal year 2027 to support one award with a maximum project period of three years. Budgets are not capped, but applicants are instructed to request only amounts necessary to support proposed activities. The project includes significant coordination responsibilities, including maintaining the AMP SCZ website, participating in publication committees, leading steering committee meetings, coordinating data sharing with the NIMH Data Archive, and collaborating with multidisciplinary experts across clinical research networks. The NOFO also emphasizes rapid and broad data sharing consistent with NIH Data Management and Sharing requirements and encourages avoidance of intellectual property claims directly derived from the shared precompetitive data generated through AMP SCZ. Eligibility for this opportunity is extremely limited because the announcement is designated as a single-source funding opportunity. Only Brigham and Women’s Hospital is eligible to apply, and only current principal investigators or program directors associated with the prior award issued under RFA-MH-20-341 may serve as eligible PDs/PIs. Foreign organizations, non-U.S. organizational components, and foreign components are expressly prohibited. Applicants must maintain active registrations in SAM.gov, Grants.gov, eRA Commons, and obtain a Unique Entity Identifier. Principal investigators must also maintain linked ORCID identifiers in eRA Commons. The NOFO allows new, renewal, and resubmission application types, but the opportunity remains restricted to the specified institution under the single-source framework. Applications must be submitted electronically through Grants.gov, ASSIST, or approved institutional system-to-system solutions. The earliest submission date is May 9, 2026, and applications are due by 5:00 PM local time on June 9, 2026. Late applications will not be accepted. The announcement was posted on May 7, 2026, and expires on June 10, 2026. Required application components include all standard NIH Research (R) application materials as well as a detailed Research Strategy, organizational structure description, data management and sharing plan, and plans for steering committee operations, shared decision-making, milestones, and publication strategies. Applications involving human subjects must include the required PHS Human Subjects and Clinical Trials Information forms, although clinical trials themselves are not permitted under this opportunity. The NOFO also requires applicants to comply with NIH Common Data Element expectations and extensive cybersecurity and reporting obligations. Applications will undergo NIH peer review according to standard scientific and technical merit criteria. Reviewers will evaluate significance, investigators, innovation, approach, and environment, along with human subjects protections, inclusion plans, budget justification, and resource sharing plans. Applications judged meritorious through peer review will proceed to second-level review by the National Advisory Mental Health Council. Funding decisions will consider scientific merit, program priorities, and availability of funds. The anticipated scientific merit review is scheduled for July 2026, council review for October 2026, and the earliest anticipated project start date is December 2026. The cooperative agreement structure also establishes ongoing joint governance responsibilities between NIH and award recipients, including biweekly steering committee meetings, milestone monitoring, and collaborative oversight of research priorities, analytic strategies, and dissemination activities. Programmatic and administrative contacts are included within the NOFO. Scientific inquiries may be directed to DNBBSInitiatives@mail.nih.gov, peer review questions to NOFOReviewContact@csr.nih.gov, and financial or grants management questions to NIMHNOFOGrantsManagement@mail.nih.gov. The NOFO additionally outlines extensive award administration conditions, cybersecurity requirements, reporting obligations, and data-sharing expectations under NIH policy. Because this is a targeted single-source continuation opportunity tied to an ongoing AMP SCZ infrastructure effort, the announcement does not indicate recurring annual competition cycles or broader public eligibility. The opportunity is therefore a non-recurring, limited federal research coordination and data analysis award intended to sustain and complete an existing national schizophrenia biomarker initiative.

Emphasize multidisciplinary expertise in longitudinal multimodal biomarker analysis and multicenter coordination. Demonstrate strong governance structures quality control systems milestone tracking and robust data-sharing infrastructure. Align proposed analyses closely with AMP SCZ scientific objectives and NIMH priorities.